Andreas Suhartoyo Winarno1,2, Anne Mondal3, Franca Christina Martignoni4, Tanja Natascha Fehm4, Monika Hampl4. 1. Department of Obstetrics and Gynecology, University Hospital of Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany. dr.andreas.winarno@gmail.com. 2. Department of Obstetrics and Gynecology, Franziskus Hospital Bielefeld, Kiskerstraße 26, 33615, Bielefeld, Nordrhein-Westfalen, Germany. dr.andreas.winarno@gmail.com. 3. Women's Clinic on Schwanenmarkt, Düsseldorf, Germany. 4. Department of Obstetrics and Gynecology, University Hospital of Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.
Abstract
BACKGROUND: Since the introduction of sentinel node biopsy (SLNB) in unifocal vulvar cancer (diameter of < 4 cm) and unsuspicious groin lymph nodes, the morbidity rate of patients has significantly decreased globally. In contrast to SLNB, bilateral inguinofemoral lymphadenectomy (IFL) has been associated with increased risk of common morbidities. Current guidelines (NCCN, ESGO, RCOG, and German) recommend that in cases of unilaterally positive sentinel lymph node (SLN), bilateral IFL should be performed. However, two recent publications by Woelber et al. and Nica et al. contradict the current guideline, since a significant rate of positive non sentinel lymph nodes in IFL contralaterally was not observed [Woelber et al. 0% (p = 0/28) and Nica et al. 5.3% (p = 1/19)]. METHODS: A retrospective single-center analysis conducted in the University Hospital of Dusseldorf, evaluating vulvar cancer patients treated with SLNB from 2002 to 2018. RESULTS: 22.2% of women (n = 4/18) were found to have contralateral IFL groin metastasis after an initial diagnosis of unilateral SLN metastasis. The depth of tumor infiltrating cells correlated significantly and positively with the rate of incidence of groin metastasis (p = 0.0038). CONCLUSION: Current guideline for bilateral IFL should remain as the standard management. Therefore, this depth may be taken into account as an indication for bilateral IFL. The management of VC and SLNB should be performed in a high volume center with an experienced team in marking SLN and performing the adequate surgical procedure. Well conducted counseling of the patients outlining advantages but also potential oncological risks of this technique especially concerning rate of groin recurrence is critical.
BACKGROUND: Since the introduction of sentinel node biopsy (SLNB) in unifocal vulvar cancer (diameter of < 4 cm) and unsuspicious groin lymph nodes, the morbidity rate of patients has significantly decreased globally. In contrast to SLNB, bilateral inguinofemoral lymphadenectomy (IFL) has been associated with increased risk of common morbidities. Current guidelines (NCCN, ESGO, RCOG, and German) recommend that in cases of unilaterally positive sentinel lymph node (SLN), bilateral IFL should be performed. However, two recent publications by Woelber et al. and Nica et al. contradict the current guideline, since a significant rate of positive non sentinel lymph nodes in IFL contralaterally was not observed [Woelber et al. 0% (p = 0/28) and Nica et al. 5.3% (p = 1/19)]. METHODS: A retrospective single-center analysis conducted in the University Hospital of Dusseldorf, evaluating vulvar cancerpatients treated with SLNB from 2002 to 2018. RESULTS: 22.2% of women (n = 4/18) were found to have contralateral IFL groin metastasis after an initial diagnosis of unilateral SLN metastasis. The depth of tumor infiltrating cells correlated significantly and positively with the rate of incidence of groin metastasis (p = 0.0038). CONCLUSION: Current guideline for bilateral IFL should remain as the standard management. Therefore, this depth may be taken into account as an indication for bilateral IFL. The management of VC and SLNB should be performed in a high volume center with an experienced team in marking SLN and performing the adequate surgical procedure. Well conducted counseling of the patients outlining advantages but also potential oncological risks of this technique especially concerning rate of groin recurrence is critical.
Authors: Wui-Jin Koh; Benjamin E Greer; Nadeem R Abu-Rustum; Susana M Campos; Kathleen R Cho; Hye Sook Chon; Christina Chu; David Cohn; Marta Ann Crispens; Don S Dizon; Oliver Dorigo; Patricia J Eifel; Christine M Fisher; Peter Frederick; David K Gaffney; Ernest Han; Susan Higgins; Warner K Huh; John R Lurain; Andrea Mariani; David Mutch; Christa Nagel; Larissa Nekhlyudov; Amanda Nickles Fader; Steven W Remmenga; R Kevin Reynolds; Todd Tillmanns; Stefanie Ueda; Fidel A Valea; Emily Wyse; Catheryn M Yashar; Nicole McMillian; Jillian Scavone Journal: J Natl Compr Canc Netw Date: 2017-01 Impact factor: 11.908
Authors: Maaike H M Oonk; François Planchamp; Peter Baldwin; Mariusz Bidzinski; Mats Brännström; Fabio Landoni; Sven Mahner; Umesh Mahantshetty; Mansoor Mirza; Cordula Petersen; Denis Querleu; Sigrid Regauer; Lukas Rob; Roman Rouzier; Elena Ulrikh; Jacobus van der Velden; Ignace Vergote; Linn Woelber; Ate G J van der Zee Journal: Int J Gynecol Cancer Date: 2017-05 Impact factor: 3.437
Authors: Brian M Slomovitz; Robert L Coleman; Maaike H M Oonk; Ate van der Zee; Charles Levenback Journal: Gynecol Oncol Date: 2015-05-27 Impact factor: 5.482
Authors: F Amant; P Berveiller; I A Boere; E Cardonick; R Fruscio; M Fumagalli; M J Halaska; A Hasenburg; A L V Johansson; M Lambertini; C A R Lok; C Maggen; P Morice; F Peccatori; P Poortmans; K Van Calsteren; T Vandenbroucke; M van Gerwen; M van den Heuvel-Eibrink; F Zagouri; I Zapardiel Journal: Ann Oncol Date: 2019-10-01 Impact factor: 32.976
Authors: Ate G J Van der Zee; Maaike H Oonk; Joanne A De Hullu; Anca C Ansink; Ignace Vergote; René H Verheijen; Angelo Maggioni; Katja N Gaarenstroom; Peter J Baldwin; Eleonore B Van Dorst; Jacobus Van der Velden; Ralph H Hermans; Hans van der Putten; Pierre Drouin; Achim Schneider; Wim J Sluiter Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Philip M Spanheimer; Michael M Graham; Sonia L Sugg; Carol E H Scott-Conner; Ronald J Weigel Journal: Ann Surg Oncol Date: 2009-03-07 Impact factor: 5.344
Authors: Sven Mahner; Julia Jueckstock; Felix Hilpert; Petra Neuser; Philipp Harter; Nikolaus de Gregorio; Annette Hasenburg; Jalid Sehouli; Annika Habermann; Peter Hillemanns; Sophie Fuerst; Hans-Georg Strauss; Klaus Baumann; Falk Thiel; Alexander Mustea; Werner Meier; Andreas du Bois; Lis-Femke Griebel; Linn Woelber Journal: J Natl Cancer Inst Date: 2015-01-24 Impact factor: 13.506